{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:12:18Z","timestamp":1793905938104,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037646"],"award-info":[{"award-number":["INV-037646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K99\/R00 MH121166"],"award-info":[{"award-number":["K99\/R00 MH121166"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV pre- and post-exposure prophylaxis (PrEP\/PEP) provision via online pharmacies could expand reach of HIV prevention in Eastern and Southern Africa, but designing sustainable delivery models will require assessing the amount potential users are willing to pay for online PrEP\/PEP provision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We administered willingness to pay (WTP) questionnaires to both potential online PrEP users and current online PrEP\/PEP users in Nairobi, Kenya using a stated preference approach to measure the amount participants were willing to pay for PrEP\/PEP service delivery components. Participants\u2009\u2265\u200918 years were recruited via banner ads on an online pharmacy website on pages displaying sexual health products. We used multivariable gamma regression models to assess characteristics associated with differences in mean WTP for a 30-day PrEP or 28-day PEP course (including HIV self-testing, remote clinical consultation, drugs, and delivery fees).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From May 2022 and December 2023, 1,512 participants completed WTP questionnaires: 772 potential online PrEP users and 740 current online PrEP\/PEP users. Most participants (98.3%, 1486\/1,512) were willing to pay some amount for online PrEP services. For a one-month PrEP supply, potential online PrEP users were willing to pay 1388 KSH ($11.77 USD) and current online PrEP\/PEP users were willing to pay 1271.2 KSH ($10.77 USD) on average. Most current online PrEP\/PEP users (81.4%, 602\/740) were also willing to pay for online PEP services; for a 28-day PEP supply, they were willing to pay 812.9 KSH ($6.89 USD) on average. Among potential online PrEP users, male sex, current enrollment in school, high income, and a history of online pharmacy purchases were associated with higher WTP for PrEP. Among current online PrEP\/PEP users, higher income and prior online pharmacy purchases were associated with higher WTP for PrEP, and older age (&gt;\u200924) and prior online pharmacy purchases were associated with higher WTP for PEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most potential and current online PrEP\/PEP users in Nairobi were willing to pay for online pharmacy-based PrEP\/PEP and demonstrated similar WTP. Providing PrEP\/PEP through online pharmacies may sustainably expand coverage of these HIV prevention services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-025-12766-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T23:29:30Z","timestamp":1745278170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Willingness to pay for HIV pre- and post-exposure prophylaxis services delivered via an online pharmacy in Kenya"],"prefix":"10.1186","volume":"25","author":[{"given":"Michalina A.","family":"Monta\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Saldarriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Thuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kiptinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Stergachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Mugambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina F.","family":"Ortblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"12766_CR1","unstructured":"Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic. United Nations Joint Program on AIDS (UNAIDS); 2023. https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/UNAIDS_FactSheet."},{"key":"12766_CR2","unstructured":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. https:\/\/www.who.int\/publications\/i\/item\/9789241509565."},{"issue":"10013","key":"12766_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53\u201360.","journal-title":"Lancet"},{"issue":"12","key":"12766_CR4","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O\u2019Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Aids. 2016;30(12):1973\u201383.","journal-title":"Aids"},{"issue":"5","key":"12766_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"key":"12766_CR6","unstructured":"In danger: UNAIDS global AIDS report 2022. United Nations Joint Program on AIDS (UNAIDS); 2022. https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in-danger-global-aids-update."},{"key":"12766_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1472-6963-14-231","volume":"14","author":"N Mack","year":"2014","unstructured":"Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14:231.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"12766_CR8","doi-asserted-by":"publisher","first-page":"21134","DOI":"10.7448\/IAS.19.1.21134","volume":"19","author":"RC Patel","year":"2016","unstructured":"Patel RC, Stanford-Moore G, Odoyo J, Pyra M, Wakhungu I, Anand K, et al. Since both of us are using antiretrovirals, we have been supportive to each other: facilitators and barriers of pre-exposure prophylaxis Use in heterosexual HIV serodiscordant couples in Kisumu, Kenya. J Int AIDS Soc. 2016;19(1):21134.","journal-title":"J Int AIDS Soc"},{"key":"12766_CR9","volume-title":"Getting HIV Pre-exposure Prophylaxis (PrEP) into Private Pharmacies: Global Delivery Models and Research Directions","author":"SD Roche","year":"2024","unstructured":"Roche SD, Were D, Crawford ND, Tembo A, Pintye J, Bukusi E, et al. Getting HIV Pre-exposure prophylaxis (PrEP) into private pharmacies: global delivery models and research directions. Curr HIV\/AIDS Rep; 2024."},{"issue":"10","key":"12766_CR10","doi-asserted-by":"publisher","first-page":"e26027","DOI":"10.1002\/jia2.26027","volume":"25","author":"AP Kuo","year":"2022","unstructured":"Kuo AP, Roche SD, Mugambi ML, Pintye J, Baeten JM, Bukusi E, et al. The effectiveness, feasibility and acceptability of HIV service delivery at private pharmacies in sub-Saharan Africa: a scoping review. J Int AIDS Soc. 2022;25(10):e26027.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"12766_CR11","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1007\/s10461-021-03229-5","volume":"25","author":"SD Roche","year":"2021","unstructured":"Roche SD, Wairimu N, Mogere P, Kamolloh K, Odoyo J, Kwena ZA, et al. Acceptability and feasibility of pharmacy-based delivery of pre-exposure prophylaxis in Kenya: a qualitative study of client and provider perspectives. AIDS Behav. 2021;25(12):3871\u201382.","journal-title":"AIDS Behav"},{"key":"12766_CR12","doi-asserted-by":"publisher","first-page":"232595822312158","DOI":"10.1177\/23259582231215882","volume":"22","author":"M Vera","year":"2023","unstructured":"Vera M, Bukusi E, Achieng P, Aketch H, Araka E, Baeten JM, et al. Pharmacies are everywhere, and you can get it at any time: experiences with pharmacy-based PrEP delivery among adolescent girls and young women in Kisumu, Kenya. J Int Assoc Provid AIDS Care. 2023;22:23259582231215882.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"suppl3","key":"12766_CR13","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1093\/cid\/civ068","volume":"60","author":"N Ford","year":"2015","unstructured":"Ford N, Mayer KH, Group ftWHOPPGD, Barlow L, Bagyinszky F, Calmy A, et al. World health organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis. 2015;60(suppl3):S161\u20134.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"12766_CR14","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1016\/S2214-109X(23)00383-2","volume":"11","author":"AN Phillips","year":"2023","unstructured":"Phillips AN, Bansi-Matharu L, Shahmanesh M, Hargreaves JR, Smith J, Revill P, et al. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in East, Central, Southern, and West Africa: a modelling analysis. Lancet Glob Health. 2023;11(10):e1648\u201357.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"12766_CR15","first-page":"281","volume":"29","author":"O Ogodo","year":"2023","unstructured":"Ogodo O. Dozens of telehealth companies are innovating in Africa. Nat Med. 2023;29(2):281\u20132.","journal-title":"Nat Med"},{"issue":"3","key":"12766_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.glohj.2021.07.006","volume":"5","author":"TY Akintunde","year":"2021","unstructured":"Akintunde TY, Akintunde OD, Musa TH, Sayibu M, Tassang AE, Reed LM, et al. Expanding telemedicine to reduce the burden on the healthcare systems and poverty in Africa for a post-coronavirus disease 2019 (COVID-19) pandemic reformation. Glob Health J. 2021;5(3):128\u201334.","journal-title":"Glob Health J"},{"key":"12766_CR17","unstructured":"Consolidated guidelines on differentiated HIV testing services. Geneva: World Health Organization; 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240096394."},{"key":"12766_CR18","doi-asserted-by":"publisher","first-page":"1054559","DOI":"10.3389\/fpubh.2023.1054559","volume":"11","author":"C Kiptinness","year":"2023","unstructured":"Kiptinness C, Naik P, Thuo N, Malen RC, Dettinger JC, Pintye J, et al. Online HIV prophylaxis delivery: protocol for the ePrEP Kenya pilot study. Front Public Health. 2023;11:1054559.","journal-title":"Front Public Health"},{"key":"12766_CR19","doi-asserted-by":"crossref","unstructured":"Kiptinness C, Naik P, Kareithi T, Thuo N, Rafferty M, Jomo E, et al. editors. Online delivery of HIV prophylaxis services in Kenya: results from the ePrEP Kenya pilot study. Munich: AIDS 2024 Conference; 2024.","DOI":"10.3389\/fpubh.2023.1054559"},{"issue":"4","key":"12766_CR20","doi-asserted-by":"publisher","first-page":"e069195","DOI":"10.1136\/bmjopen-2022-069195","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen Y, Saldarriaga EM, Montano MA, Ngure K, Thuo N, Kiptinness C, et al. Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment. BMJ Open. 2023;13(4):e069195.","journal-title":"BMJ Open"},{"key":"12766_CR21","unstructured":"PrEP Rapid Assessment Screening Tool. Kenya Ministry of Health: National AIDS and STIs Control Program. 2017. https:\/\/www.scribd.com\/document\/561639646\/pmed-1002885-s003."},{"key":"12766_CR22","unstructured":"Sawtooth Software. The CBC system for Choice-Based conjoint analysis. Version 9 ed. https:\/\/sawtoothsoftware.com\/conjoint-analysis\/cbc."},{"issue":"4","key":"12766_CR23","first-page":"1","volume":"2","author":"C Breidert","year":"2006","unstructured":"Breidert C, Hahsler M, Reutterer T. A review of methods for measuring willingness-to-pay. Innov Mark. 2006;2(4):1\u201332.","journal-title":"Innov Mark."},{"issue":"10","key":"12766_CR24","doi-asserted-by":"publisher","first-page":"e26356","DOI":"10.1002\/jia2.26356","volume":"27","author":"EM Saldarriaga","year":"2024","unstructured":"Saldarriaga EM, Chen Y, Monta\u00f1o MA, Thuo N, Kiptinness C, Terris-Prestholt F, et al. Preferences for pre-exposure prophylaxis delivery via online pharmacy among potential users in Kenya: a discrete choice experiment. J Int AIDS Soc. 2024;27(10):e26356.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"12766_CR25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/0956462420912141","volume":"31","author":"ER Begnel","year":"2020","unstructured":"Begnel ER, Escudero J, Mugambi M, Mugwanya K, Kinuthia J, Beima-Sofie K, et al. High pre-exposure prophylaxis awareness and willingness to pay for pre-exposure prophylaxis among young adults in Western Kenya: results from a population-based survey. Int J STD AIDS. 2020;31(5):454\u20139.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"12766_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9745\/GHSP-D-21-00303","volume":"10","author":"O Durosinmi-Etti","year":"2022","unstructured":"Durosinmi-Etti O, Nwala EK, Oki F, Ikpeazu A, Godwin E, Umoh P, et al. Willingness to pay for HIV prevention commodities among key population groups in Nigeria. Glob Health Sci Pract. 2022;10(5):1\u201313. https:\/\/doi.org\/10.9745\/GHSP-D-21-00303.","journal-title":"Glob Health Sci Pract."},{"key":"12766_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.socscimed.2019.04.015","volume":"232","author":"L Kanya","year":"2019","unstructured":"Kanya L, Sanghera S, Lewin A, Fox-Rushby J. The criterion validity of willingness to pay methods: a systematic review and meta-analysis of the evidence. Soc Sci Med. 2019;232:238\u201361.","journal-title":"Soc Sci Med"},{"issue":"2","key":"12766_CR28","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/QAI.0000000000001659","volume":"78","author":"H Thirumurthy","year":"2018","unstructured":"Thirumurthy H, Masters SH, Agot K. Willingness to pay for HIV Self-Tests among women in Kenya: implications for subsidy and pricing policies. J Acquir Immune Defic Syndr. 2018;78(2):e8\u201311.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"12766_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40271-020-00486-9","volume":"14","author":"SW Beckham","year":"2021","unstructured":"Beckham SW, Crossnohere NL, Gross M, Bridges JFP. Eliciting preferences for HIV prevention technologies: a systematic review. Patient. 2021;14(2):151\u201374.","journal-title":"Patient"},{"issue":"2","key":"12766_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/heapol\/17.2.187","volume":"17","author":"S Forsythe","year":"2002","unstructured":"Forsythe S, Arthur G, Ngatia G, Mutemi R, Odhiambo J, Gilks C. Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy Plan. 2002;17(2):187\u201395.","journal-title":"Health Policy Plan"},{"issue":"12","key":"12766_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2165\/11314000-000000000-00000","volume":"27","author":"TA Lieu","year":"2009","unstructured":"Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes Zoster. PharmacoEconomics. 2009;27(12):1005\u201316.","journal-title":"PharmacoEconomics"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12766-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12766-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12766-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T23:29:35Z","timestamp":1745278175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12766-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12766"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12766-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees, and with the 1964 Helsinki declaration and its later amendments of comparable ethical standards. The study received ethical approval from the Scientific and Ethics Review Unit at the Kenya Medical Research Institute and Institutional Review Board at the University of Washington. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"576"}}